3-methyl 5-(1-methylethyl) 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate | 95445-79-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-methyl 5-(1-methylethyl) 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
• 英文别名: 3,5-Pyridinedicarboxylic acid, 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-, 3-methyl 5-(1-methylethyl) ester；3-O-methyl 5-O-propan-2-yl 4-[3-chloro-6-fluoro-2-(trifluoromethyl)phenyl]-2-(fluoromethyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylate
• CAS: 95445-79-7
• 化学式: C₂₀H₁₉ClF₅NO₄
• 分子量: 467.82
• InChiKey: OBWJAVIHPMZUHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  31
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  64.6
• 氢给体数：
  1
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  3-methyl 5-(1-methylethyl) 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate 在 吡啶 、 pyridinium hydrobromide perbromide 作用下， 以 氯仿 为溶剂， 生成 5-methyl 3-(1-methylethyl) 2-(bromomethyl)-4-<3-chloro-6-fluoro-2-(trifluoromethyl)-phenyl>-6-(fluoromethyl)-1,4-dihydropyridine-3,5-dicarboxylate
  参考文献：
  名称：

  EP225175

  摘要：

  公开号：
• 作为产物：
  描述：

  3-氯-6-氟-2-(三氟甲基)苯甲醛 、 methyl 4-fluoro-3-oxo-butanoate 、 3-氨基巴豆酸异丙酯 在 氮气 、 silica 、 二氯甲烷 作用下， 反应 4.0h， 以The title compound (0.2 g) was obtained的产率得到3-methyl 5-(1-methylethyl) 4-(3-chloro-6-fluoro-2-(trifluoromethyl)phenyl)-2-(fluoromethyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylate
  参考文献：
  名称：

  Calcium antagonist 2-fluoroalkyl-1,4-dihydropyridines

  摘要：

  描述了一系列化合物的化学式I，其中R.sub.1代表苯并呋喃基、吡啶基或苯基，吡啶基或苯基被取代，--COOR.sub.2和--COOR.sub.3是不同的酯基，R.sub.7和R.sub.8中的一个代表烷基Cl至6，另一个代表--CONR.sub.10 R.sub.11；--CSNH.sub.2；--C(.dbd.NH)SR.sub.9；--S(O).sub.mR.sub.9；苯基选择性地被取代为1个或多个烷基Cl至6、卤素、烷氧基Cl至6或硝基；被卤素取代的烷基Cl至6；或呋喃基；m为0或1，R.sub.9为烷基Cl至6，R.sub.10和R.sub.11各自独立地表示氢或烷基Cl至6，或者与它们所附着的氮原子一起形成5或6元杂环环。还描述了制备这些化合物的过程以及包含它们的制药配方，例如钙拮抗剂。

  公开号：

  US04686217A1

文献信息

• A novel, base-induced fragmentation of hantzsch-type 4-aryl-1,4-dihydropyridines
  作者：Thomas McInally、Alan C. Tinker

  DOI：10.1039/p19880001837

  日期：——

  Hantzsch-type 1,4-dihydropyridine derivatives substituted with highly electron-deficient aryl groups in the 4-position, on treatment with a variety of basic reagents in non-hydroxylic solvents, undergo an unexpected and ready scission of the inter-ring bond to give the corresponding 4-unsubstituted pyridine and an arene derived from the original 4-substituent. The scope of the reaction has been investigated

  在非羟基溶剂中用多种碱性试剂处理后，在4位上被高度缺电子的芳基取代的Hantzsch型1,4-二氢吡啶衍生物经历了意想不到的即刻断裂的环间键得到相应的4-未取代的吡啶和衍生自原始4-取代基的芳烃。已经研究了反应的范围并讨论了可能的机理。
• Pharmaceutically active dihydropyridines
  申请人：FISONS plc

  公开号：EP0125803A2

  公开（公告）日：1984-11-21

  There are described compounds of formula I, in which R1 represents benzofurazanyl, pyridyl or phenyl, the pyridyl or phenyl being substituted, -COOR2 and -COOR3 are various ester groups, Yand Ztogetherform a bond, and additionally, when R. is an electron withdrawing group Y may be hydrogen and Z may be hydroxy, one of R7 and R. represents alkyl Cl to 6 and the other represents -CONR10R11; -CSNH2; -C(=NN)SR9; -S(O)mR9; phenyl optionally substituted by one or more of alkyl Cl to 6, halogen, alkoxy CI to 6 or nitro; alkyl Cl to 6 substituted by halogen; or furanyl, or R7 and R. may be the same or different and each represents phenyl optionally substituted by one or more of alkyl CI to 6, halogen, alkoxy Cl to 6 or nitro; amino; alkyl CI to 6 substituted by halogen; -CN; -CH2OH; -CHO or-CH(OR9)2, m is 0 or 1 R9 is alkyl CI to 6, and R10 and R11 each independently represent hydrogen or alkyl Cl to 6, or together with the nitrogen atom to which they are attached form a 5 or 6 membered heterocyclic ring. There are also described processes for making the compounds, and pharmaceutical, eg calcium antagonist, formulations containing them.

  所述化合物为式 I、 其中 R1 代表苯并呋喃基、吡啶基或苯基，吡啶基或苯基被取代、 -COOR2和-COOR3是各种酯基、 Y和Z共同构成键，此外，当R.是取电子基团时，Y可以是氢，Z可以是羟基、 R7 和 R. 中的一个代表 Cl 至 6 烷基，另一个代表-CONR10R11；-CSNH2；-C(=NN)SR9；-S(O)mR9；任选被 Cl 至 6 烷基、卤素、CI 至 6 烷氧基或硝基中的一个或多个取代的苯基；被卤素取代的 Cl 至 6 烷基；或呋喃基、 或 R7 和 R.可以相同或不同，且各自代表被以下一种或多种任选取代的苯基：CI 至 6 号烷基、卤素、CI 至 6 号烷氧基或硝基；氨基；被卤素取代的 CI 至 6 号烷基；-CN；-CH2OH；-CHO 或-CH(OR9)2、 m为0或1 R9 是 CI-6 烷基，和 R10和R11各自独立地代表氢或Cl至6的烷基，或与它们所连接的氮原子一起形成5或6个成员的杂环。 此外，还介绍了制造这些化合物的工艺，以及含有这些化合物的药物制剂（如钙拮抗剂）。
• Dihydropyridines, processes and intermediates for their production, and pharmaceutical formulations containing them
  申请人：FISONS plc

  公开号：EP0174131A2

  公开（公告）日：1986-03-12

  There are described compounds of formula 1, in which R,, R2, R3, Rs and R6 are as defined in the specification and R4 is a phenyl group carrying 3 or 4 substituents or is an unsaturated 5 membered heterocyclic group containing a single hetero-atom selected from oxygen, sulphur or nitrogen, R4 being substituted by CF3, XR22, nitro, halogen, CN, alkyl C1 to 6, formyl dioxalanyl, -N(R23)COR24 -CONR25R26, or amino which is optionally substituted by phenylsulphonyl or by trifluoroacetyl, and R4 carries a substituent on the atom adjacent to the atom through which R4 is connected to the remainder of the molecule, R22 is phenyl or alkyl C1 to 6 optionally substituted by halogen, X is 0 or S(O)n, n is 0, 1 or 2, and R23, R24, R25 and R26, which may be the same or different, are each hydrogen or alkyl C1 to 6. There are also described methods for making the compounds, and their formulation and use as pharmaceuticals, eg for the treatment of cardiovascular conditions. There are further described compounds R4CHO which are useful in making compounds of formula I.

  所述化合物为式 1、 其中 R,、R2、R3、Rs 和 R6 如说明书中所定义，R4 是带有 3 或 4 个取代基的苯基，或者是含有一个选自氧、硫或氮的杂原子的不饱和 5 位杂环基团，R4 被 CF3、XR22、R4被 CF3、XR22、硝基、卤素、CN、C1-6 烷基、二噁烷甲酰基、-N(R23)COR24-CONR25R26 或任选被苯磺酰基或三氟乙酰基取代的氨基取代，且 R4 在与 R4 通过其与分子其余部分相连的原子相邻的原子上带有一个取代基、 R22 是苯基或任选被卤素取代的 C1 至 6 烷基、 X 是 0 或 S(O)n、 n 是 0、1 或 2，以及 R23、R24、R25 和 R26（可以相同或不同）各自为氢或 C1-6 烷基。 还描述了制造这些化合物的方法，以及它们作为药物的配制和使用，例如用于治疗心血管疾病。 此外，还描述了可用于制造式 I 化合物的 R4CHO 化合物。
• Dihydropyridine derivatives, processes for their preparation and pharmaceutical compositions thereof
  申请人：FISONS plc

  公开号：EP0225175A2

  公开（公告）日：1987-06-10

  There are described compounds of Formula I, in which R₁, R₂, R₃ and R₄ are as defined in the specification, R₅ is alkyl optionally interrupted by an amide group and optionally substituted by halogen or by a carboxy or a heterocyclic group, X is -O-, -NR-, -S(O)m₁, or a bond, Z is hydrogen or together with R forms a bond, R is hydrogen, alkyl or together with Z forms a bond, R₆ is a 5 or 6 membered unsaturated nitrogen containing heterocyclic ring, optionally fused to a phenyl ring and optionally substituted by one or more of oxo, hydroxy, alkyl, -(CH₂)n₁NH₂, alkoxy, phenyl or -COOH, and when X is -NR- or -S(O)m₁-, R₆ may in addition be hydrogen or a group -CH₂CH₂NH₂, -CH₂CH₂-het. or NHC(=NH)NH₂, when X is -O-, R₆ may also be a group -NH₂, -C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ or CH₂CH₂OCH₂CH₂NR₁₄R₁₅, when X is -NR-, -S(O)m₁-, or a bond, R₆ may also be hydrogen or a group -C(=NR₁₂)NHR₁₃, R₁₃ and R₁₄ may be hydrogen or alkyl, R₁₂ is hydrogen, alkylcarbonyl, nitrile or hydroxy, R₁₅ is hydrogen or a group R₁₁, m and m₁ are each 0, 1 or 2, n is 0 or 1, n₁ is an integer from 0 to 6 and pharmaceutically acceptable salts, esters, amides, analogues and protected derivatives thereof.

  所述化合物为式 I、 其中 R₁、R₂、R₃ 和 R₄ 如说明书中所定义、 R₅ 是任选被酰胺基打断并任选被卤素或羧基或杂环基取代的烷基、 X 是-O-、-NR-、-S(O)m₁ 或键、 Z 是氢，或与 R 形成键、 R 是氢、烷基或与 Z 共同形成键、 R₆ 是 5 或 6 个成员的不饱和含氮杂环，可选择与苯基环融合，并可选择被氧 化物、羟基、烷基、-(CH₂)n₁NH₂、烷氧基、苯基或-COOH 中的一个或多个取代、 当 X 为-NR-或-S(O)m₁-时，R₆ 还可以是氢或基团-CH₂CH₂NH₂、-CH₂CH₂-热或 NHC(=NH)NH₂ 、 当 X 为 -O- 时，R₆ 也可以是基团 -NH₂、-C(=O) (CH₂)nNH₂, -CH₂CH₂NR₁₄R₁₅ 或 CH₂CH₂OCH₂CH₂NR₁₄R₁₅、 当 X 为-NR-、-S(O)m₁- 或键时，R₆ 也可以是氢或基团-C(=NR₁₂)NHR₁₃、 R₁₃ 和 R₁₄ 可以是氢或烷基、 R₁₂ 是氢、烷基羰基、腈或羟基、 R₁₅ 是氢或基团 R₁₁、 m 和 m₁ 均为 0、1 或 2、 n 为 0 或 1、 n₁ 是 0 至 6 的整数 及其药学上可接受的盐、酯、酰胺、类似物和受保护的衍生物。
• MCINALLY, THOMAS;TINKER, ALAN C., J. CHEM. SOC. PERKIN TRANS. PT 1,(1988) N 7, C. 1837-1844
  作者：MCINALLY, THOMAS、TINKER, ALAN C.

  DOI：——

  日期：——